- Nevparin for injection 25.000 IU/5 mL, 1 vial
Composition
Each vial contains 5000 IU/mL heparin sodium.
Features
- Has anticoagulant properties
- Acts at multiple sites in normal coagulation system
- Inhibits reactions that lead to clotting of blood and the formation of fibrin clots both in vitro and in vivo
- Inhibits the conversion of prothrombin to thrombin
- Prevents the conversion of fibrinogen to fibrin
- Does not reduce the concentration of the coagulation factors but inhibits their activity
Indications
Anticoagulant therapy in;
- Thrombosis
- Prevention of thrombosis
- Embolism
- Myocardial infarction
- Prophylaxis and treatment of thrombosis
- Prevention of coagulation during hemodialysis
Contraindications
Heparin sodium should not be used in patiens with severe thrombocytopenia and uncontrollable active bleeding state.
Warnings and Precautions
To prevent a post-operative bleeding, heparin should not be administered within 3-4 days (even more) of a surgical operation; this process is shorter in heart surgery. Any unexpected situation is out of this rule. Patients treated with NEVPARIN should be closely observed. Other injectable drugs should not be administered intramuscularly during anticoagulant therapy; however, if needed, intravenous route should be used.
Adverse Reactions
Hemorrhage, hypersensitivity reactions and thrombocytopenia have been reported.
Drug Interactions
Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is to be given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn. Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacine, dipyridamole, hydroxychloroquin, and others that interfere with platelet aggregation reactions may induce bleeding and should be used with caution in patients receiving heparin sodium. Digitalis, tetracyclines, nicotine or antihistamines may partially counteract the anticoagulant action of heparin sodium.
Dosage and Administration
Total daily heparin dose should not be less than 40000 IU. In mild or moderate cases 8-10 mL (40000-50000 IU) NEVPARIN may be administered by intravenous injection in 3-4 divided doses.In severe thrombosis and embolism, the total daily dosage is 16 mL (80000 IU) given in 4 divided doses. In life-threatening situations, 5 mL (25000 IU) NEVPARIN should be administered immediately; then if it’s required to continue the therapy, 4 mL (20000 IU) should be administered intravenously every 4 hours (total daily dose is 125000 IU). In the long-term therapy of arteriosclerosis with no risk of thrombosis and embolism, 0.5-1 mL NEVPARIN can be injected intravenously or subcutaneously 2-3 times a week.
Overdosage
Bleeding is the major sign of heparin overdosage. Nose-bleedings, blood in urine or tarry stools may be noted as the first signs of bleeding.When clinical circumstances (bleeding) require reversal of heparinization, protamine sulfate (1 % solution) by slow infusion will neutralize heparin sodium. No more than 50 mg should be administered, very slowly, in any 10 minute period. Each mg of protamine sulfate neutralizes approximately 100 USP heparin units. The amount of protamine required decreases over time as heparin is metabolized.
Storage Conditions
Should be kept out of reach of children, at room temperature (< 25ºC) and in its package.
Available Forms
NEVPARİN for injection 25000 IU, 1 vial (5 mL)
Name And Address Of The Authorisation Holder
Mustafa Nevzat Ilaç Sanayii A.Ş. Prof. Dr. Bülent Tarcan Sok., Pak Iş Merkezi No: 5/1 34349 Gayrettepe/Istanbul.
Name And Address Of The Manufacturing Company
Mustafa Nevzat Ilaç Sanayii A.Ş. ÇobançeşmeMah.Sanayi Cad. No:13 Yenibosna-Istanbul.
